LOVAZA Drug Patent Profile

When do Lovaza patents expire, and when can generic versions of Lovaza launch?

Lovaza is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovaza

A generic version of LOVAZA was approved as omega-3-acid ethyl esters by GLW on April 7^th, 2014.

Summary for LOVAZA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	82
Patent Applications:	1,016
Drug Prices:	Drug price information for LOVAZA
What excipients (inactive ingredients) are in LOVAZA?	LOVAZA excipients list
DailyMed Link:	LOVAZA at DailyMed

See drug prices for LOVAZA

See drug sales revenues for LOVAZA

Recent Clinical Trials for LOVAZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prisma Health-Midlands	Phase 2/Phase 3
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
James and Esther King Biomedical Research Program	Phase 2

See all LOVAZA clinical trials

Pharmacology for LOVAZA

Drug Class

Omega-3 Fatty Acid

Paragraph IV (Patent) Challenges for LOVAZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOVAZA	Capsules	omega-3-acid ethyl esters	1 g	021654	3	2008-11-10

US Patents and Regulatory Information for LOVAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	AB	RX	Yes	Yes

Expired US Patents for LOVAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004

International Patents for LOVAZA

See the table below for patents covering LOVAZA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1534807
Greece	1000567	ΣΥΝΘΕΣΙΣ ΛΙΠΑΡΟΥ ΟΞΕΟΣ. (A FATTY ACID COMPOSITION)
United Kingdom	2221843	FATTY ACID COMPOSITION
Luxembourg	87570

Market Dynamics and Financial Trajectory for LOVAZA

Last updated: February 20, 2026

What are the current market conditions for LOVAZA?

LOVAZA (omega-3-acid ethyl esters A and B) is a prescription omega-3 fatty acid medication primarily indicated for reducing triglyceride levels in adults. The market for prescription omega-3 therapies grew steadily over the past decade, driven by increasing awareness of cardiovascular risk management and expanding indications.

As of 2023, the global omega-3 pharmaceutical market was valued at approximately $2.5 billion. The segment dominated by LOVAZA accounts for nearly $600 million, with North America contributing 70% of revenues. Market growth is expected to compound annually at around 6% through 2028.

Major competitors include Vascepa (icosapent ethyl), introduced in 2012, which has gained market share following the FDA approval for cardiovascular risk reduction in 2019 (Vascepa is marketed by Amarin Corporation). The rivalry has intensified particularly after Vascepa's expanded label, leading to a more fragmented market.

Key factors influencing market conditions include:

• Increased prevalence of hypertriglyceridemia.
• Clinical guidelines endorsing omega-3 therapy for cardiovascular risk.
• Patent expirations affecting market exclusivity.
• The emergence of generic and biosimilar formulations.

How does patent status influence LOVAZA's financial outlook?

Lovaaza’s original patent expired in 2011, but formulations and manufacturing processes have been protected through supplementary patents and exclusivities, extending market exclusivity until around 2025 in mature markets.

Patent cliffs have led to increased generic competition, pressuring pricing and margins. Despite this, the brand retains a foothold in the market due to provider familiarity and formulary positioning.

The loss of patent protection is projected to cause revenue declines of 15-20% annually from 2025 onward, unless new formulations or indications secure additional exclusivity.

What are the regulatory considerations affecting LOVAZA?

LOVZA was approved by the FDA in 2000. The key regulatory milestones include:

• 2019: Vascepa clearance for cardiovascular event reduction.

• 2020: Label updates emphasizing cardiovascular benefits, shifting market dynamics.

LOVAZA has not received additional new indications; thus, regulatory flexibility remains limited. Ongoing discussions about expanding lipid management labels may influence future sales.

How are commercial strategies shaping the revenue trajectory?

Pfizer, the current marketer of LOVAZA, has emphasized pediatric dosing and broad lipid management to maintain competitiveness. Evidence-based positioning aligned with guidelines from American Heart Association (AHA) and European Society of Cardiology (ESC) supports sustained use.

However, patent expiration prompts the company to:

• Focus on patient adherence programs.
• Negotiate favorable formulary placements.
• Invest in clinical studies to support future indications.

Pricing strategies have shifted towards value-based models, with discounts and rebates to maximize market penetration.

What is the outlook considering market expansion and pipelines?

Upcoming opportunities include:

• New formulations (e.g., extended-release capsules) to improve compliance.
• Potential new indications, such as hypo-triglyceridemia management in combination with statins.
• Entry into emerging markets with growing cardiovascular disease burdens, such as Asia-Pacific.

Market expansion efforts face regulatory and reimbursement hurdles but represent potential growth avenues. Contract manufacturing alliances and commercialization partnerships may influence sales volume.

Financial projections overview

Year	Revenue (USD million)	Growth Rate	Key Notes
2023	580	N/A	Mature market; intense competition
2024	550	-5%	Price pressure continues
2025	440	-20%	Patent expiry influence
2026	400	-9%	Generic competition increases
2027	390	-2.5%	Market stabilization

Key Takeaways

• LOVAZA operates in a competitive omega-3 segment with rising generic pressures post-patent expiry.
• The product's revenue decline is projected to accelerate after 2025 due to patent cliffs but may stabilize with new formulations and indications.
• Market expansion into emerging regions and formulation innovations could offset some losses.
• Reimbursement negotiations and formulary positioning will influence long-term profitability.
• Clinical management guidelines heavily influence market demand.

FAQs

What are the main competitors to LOVAZA?
Vascepa (Amarin), Lovaza's primary competitor, gained FDA approval for cardiovascular risk reduction, capturing significant market share.

Will LOVAZA regain market share after patent expiry?
Recovery depends on new indications, formulations, and favorable reimbursement, which are uncertain amidst generic competition.

How does regulatory change affect LOVAZA's future?
Any new FDA or EMA approvals for expanded use could positively impact sales; regulatory challenges may delay development.

Are alternative therapies reducing LOVAZA’s market?
Yes; statin and other lipid-lowering therapies, along with non-prescription omega-3s, diminish demand for prescription LOVAZA.

What is the outlook for LOVAZA's pipeline?
No current pipeline developments are publicly announced; future growth hinges on new formulations or indications.

---

References

1. MarketWatch. (2023). Omega-3 fatty acids market size, share, trends, and forecast. Retrieved from https://www.marketwatch.com
2. FDA. (2021). Vascepa label updates and indications. U.S. Food and Drug Administration.
3. Pfizer. (2022). LOVAZA product information. Pfizer Inc.
4. European Society of Cardiology. (2020). Lipid management guidelines. ESC.
5. Amarin. (2019). Vascepa approved for cardiovascular risk reduction. Amarin Reports.